Paraza Pharma, a Canada based, fully integrated drug discovery organisation, announced on Monday that it has named Edward W (Ted) Marple, AB (Harvard), MBA (Virginia) as its new executive vice-president, Development.
Marple has over 20 years of experience as a senior executive with wide skill sets across clinical development, IP protection, manufacturing, operations, company and product strategy, finance, and commercial partnering/development in the biotechnology and pharmaceutical industry.
Arshad Siddiqui, Ph.D., Paraza founder and CEO, said, 'We are excited to have Ted join Paraza's senior leadership team as we continue to expand our capabilities to better serve our client-partners. Ted's extensive business and commercial expertise will be invaluable to Paraza as we continue to partner with biotechnology and pharmaceutical companies to accelerate research, development and access to new and better treatments for patients.'
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study